Memo inOncology SPECIAL ISSUE congress report ASCO 2021- Lung Cancer is now available!

This report highlights immunotherapeutic standards in early-stage lung cancer. Moreover, strategies against sensitizing and resistance-mediating EGFR mutations as well as current perspectives regarding KRAS, MET, ROS1 and HER2 mutations are covered. Furthermore, immunotherapies and immunosupportive mechansims via e.g. anti-angiogenesis are addressed. Last but not least, this special issue includes a section about new vistas for patients with SCLC and expert interviews regarding resistance as one of the biggest challenges with targeted therapies.

As an additional feature, you will find expert video interviews with Martin Reck, Luis Paz-Ares, David T. Cooke, Donald Harvey, and Ferdinandos Skoulidis on different conference highlights on our website.